# Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

> **NCT00484536** · PHASE2 · TERMINATED · sponsor: **UCB Pharma** · enrollment: 232 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** CDP323
- **DRUG:** placebo
- **DRUG:** CDP323

## Key facts

- **NCT ID:** NCT00484536
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2009-11
- **Final completion:** 2010-07
- **Target enrollment:** 232 (ACTUAL)
- **Why stopped:** The study was discontinued due to unfavorable interim analysis
- **Last updated:** 2011-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484536, "Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00484536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*